Move to topTop

TOKYO, JAPAN - March 26, 2020 - Terumo Corporation (TSE: 4543) today announced that it has established the Group's new target to reduce greenhouse gas (GHG) emissions set for fiscal year 2030. The Group's target was approved, is considered science-based by the international organization known as Science Based Targets initiative (SBTi). The target is classified to be aligned with the "well-below 2 degrees", which was just defined by the latest SBTi Criteria (4.0) on October 2019. The category means that the target contributes to keeping a global temperature rise this century well below 2 degrees Celsius above pre-industrial levels.

Reducing the environmental negative impact of business activities is a social responsibility for companies that must be fulfilled in order to realize a sustainable society as well as an important measure for achieving sustainable growth.
In order to mitigate climate change risks, companies are now expected to set science-based GHG emission reduction targets and to work toward the achievement of these targets in order to contribute to accomplishing the Paris Agreement's central aim.

The Company is striving to reduce GHG emissions and waste, effectively use energy and resources, and develop environmentally friendly and safe products. The SBTi's approval will further drive Terumo to continue making group-wide efforts to mitigate the global challenge of climate change risks.

Terumo Group's target of GHG emission reduction

Reduce absolute Scope 1 and 2 GHG emissions 30% by 2030 from a 2018 base year
Reduce Scope 3 GHG emissions 60% per unit of revenue by 2030 from a 2018 base year

(Scope definition)
Scope 1: Direct GHG emissions by the company (e.g. fuel combustion)
Scope 2: Electricity indirect GHG emissions (e.g. GHG emissions from electric companies)
Scope 3: Other indirect GHG emissions (e.g. production of purchased materials, transportation, and waste disposal)

  • 20200326.jpg

About SBTi

The Science Based Targets initiative champions science-based target setting as a powerful way of boosting companies' competitive advantage in the transition to the low-carbon economy. It is a collaboration between CDP, the United Nations Global Compact, World Resources Institute, and the World Wide Fund for Nature. The SBTi approves companies based on the Paris Agreement, which central aim is to strengthen the global response to the threat of climate change by keeping a global temperature rise this century well below 2 degrees Celsius above pre-industrial levels and to pursue efforts to limit the temperature increase even further to 1.5 degrees Celsius. All existing SBTi approved targets are classified under three categories: 1.5 degrees, well-below 2 degrees or 2 degrees. Since October 2019, companies have to set targets against the 1.5 degrees or well-below 2 degrees criteria.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.


Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.